NEOPHORE

• 72110 - Research and experimental development on biotechnology

NeoPhore was launched in November 2017 with a total investment of £6M by Sixth Element Capital LLP and benefitted from a £1M Innovate UK BioMedical Catalyst Award. In 2021, NeoPhore raised an additional £15.2M in a Series B round led by Claris Ventures. 2Invest AG, 3B Future Health Fund, Astellas Venture Management and Sixth Element Capital LLP also participated in the round... Our compounds target components of the MMR pathway that have been validated in both clinical and preclinical studies. These components are known to modulate neoantigen creation and diversity across numerous cancers... NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.

Also known as: NEOPHORE LIMITED, Neophore Ltd

Registration numbers: 10762171 (CH)

Primary location: Altrincham United Kingdom